Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | AOC2 | O75106 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444854 | 1.00 | LOXL2 (0.43) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL18856426 | 0.80 | TRPA1 (0.45) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL21284927 | 0.79 | IDO1 (0.39) | IDO1 | |
| SCHEMBL20825046 | 0.79 | TAAR1 (0.40) | TAAR1IDO1AGXTMAOBMAOA | |
| SCHEMBL12809801 | 0.79 | LOXL2 (0.43) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL2269305 | 0.79 | LOXL2 (0.43) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL20115464 | 0.79 | TAAR1 (0.40) | TAAR1MAOASMN1; SMN2SLC6A4 | |
| SCHEMBL20825150 | 0.79 | TAAR1 (0.55) | TAAR1 | |
| SCHEMBL2268274 | 0.79 | LOXL2 (0.43) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL7435082 | 0.79 | TAAR1 (0.46) | TAAR1IDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008073458-A2 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING S.P.A. (IT) | 2008-06-19 | — | — | WO | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | LOXL2 3067/4885TRPA1 4562/4885TAAR1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.